Does taltz cause diarrhea?

See the DrugPatentWatch profile for taltz

Does Taltz cause diarrhea?

Taltz (ixekizumab) can cause diarrhea in some patients. Clinical trials reported diarrhea in about 2 percent of people taking the drug for psoriasis or psoriatic arthritis.

Why do some patients experience diarrhea?

Diarrhea is listed as a possible side effect in the prescribing information. It is usually mild and occurs early in treatment, though the exact mechanism is not fully understood.

How common is diarrhea compared with other side effects?

In the same trials, more frequent reactions included injection-site reactions and upper respiratory infections. Diarrhea ranked lower but still appeared more often than in people receiving placebo.

What should I do if diarrhea starts after beginning Taltz?

Contact your prescriber if diarrhea becomes severe, persists beyond a few days, or is accompanied by fever, dehydration, or abdominal pain. Your doctor may adjust the dosing schedule or investigate other causes.

Are there ways to manage mild diarrhea while staying on Taltz?

Simple steps such as staying hydrated, avoiding spicy or high-fiber foods, and using over-the-counter antidiarrheal medication can help in mild cases. Always check with a healthcare provider before adding any new medication.

When does the risk of diarrhea appear highest?

Most reports occur within the first few weeks of starting therapy. The frequency tends to decrease as treatment continues.

Can Taltz-related diarrhea signal something more serious?

Persistent or bloody diarrhea may indicate inflammatory bowel disease, which has been observed rarely in patients receiving IL-17 inhibitors like Taltz. Prompt medical evaluation is recommended if these symptoms develop.

What other drugs are used when diarrhea limits Taltz use?

Physicians may switch patients to alternative psoriasis or psoriatic arthritis treatments such as TNF inhibitors or IL-23 blockers that have different gastrointestinal side-effect profiles.

When does Taltz's patent expire?

The composition-of-matter patent for ixekizumab is listed as expiring in 2028, with possible extensions. DrugPatentWatch.com